Brokerages expect Concert Pharmaceuticals Inc (NASDAQ:CNCE) to post earnings of ($0.18) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Concert Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.53) and the highest is $0.17. Concert Pharmaceuticals posted earnings per share of ($0.54) during the same quarter last year, which would suggest a positive year over year growth rate of 66.7%. The business is scheduled to announce its next earnings report before the market opens on Thursday, March 1st.
According to Zacks, analysts expect that Concert Pharmaceuticals will report full year earnings of $4.10 per share for the current fiscal year, with EPS estimates ranging from $3.64 to $4.55. For the next fiscal year, analysts expect that the company will report earnings of ($2.35) per share, with EPS estimates ranging from ($2.39) to ($2.31). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Concert Pharmaceuticals.
CNCE has been the topic of several recent analyst reports. BidaskClub upgraded shares of Concert Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 9th. UBS Group set a $34.00 price objective on shares of Concert Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 19th. TheStreet upgraded shares of Concert Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Monday, January 8th. ValuEngine lowered shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 16th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $27.00 price objective on shares of Concert Pharmaceuticals in a report on Friday, January 12th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $24.33.
Concert Pharmaceuticals (NASDAQ:CNCE) traded down $0.02 during trading on Friday, hitting $22.10. 198,820 shares of the company’s stock traded hands, compared to its average volume of 457,162. The firm has a market cap of $495.30, a PE ratio of 5.95 and a beta of 1.23. Concert Pharmaceuticals has a one year low of $9.24 and a one year high of $30.71.
In related news, Director Richard Aldrich sold 11,946 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $20.89, for a total value of $249,551.94. Following the transaction, the director now owns 286,975 shares in the company, valued at $5,994,907.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ronald W. Barrett sold 14,156 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $24.70, for a total transaction of $349,653.20. Following the completion of the transaction, the director now owns 3,539 shares in the company, valued at approximately $87,413.30. The disclosure for this sale can be found here. Insiders sold 1,433,248 shares of company stock worth $37,226,329 in the last 90 days. 10.10% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new position in Concert Pharmaceuticals in the third quarter valued at approximately $153,000. Metropolitan Life Insurance Co. NY purchased a new position in Concert Pharmaceuticals in the fourth quarter valued at approximately $164,000. Alliancebernstein L.P. purchased a new position in Concert Pharmaceuticals in the second quarter valued at approximately $174,000. The Manufacturers Life Insurance Company raised its stake in shares of Concert Pharmaceuticals by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 287 shares during the period. Finally, Princeton Capital Management Inc. purchased a new stake in shares of Concert Pharmaceuticals during the third quarter valued at approximately $215,000. Hedge funds and other institutional investors own 76.61% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Analysts Expect Concert Pharmaceuticals Inc (CNCE) to Announce -$0.18 EPS” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/analysts-expect-concert-pharmaceuticals-inc-cnce-to-announce-0-18-eps.html.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.